BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Celgene (CELG): Play offense and defense with biotech]]>http://www.bloggingstocks.com/2009/06/22/celgene-celg-play-offense-and-defense-with-biotech/http://www.bloggingstocks.com/2009/06/22/celgene-celg-play-offense-and-defense-with-biotech/http://www.bloggingstocks.com/2009/06/22/celgene-celg-play-offense-and-defense-with-biotech/#commentsFiled under: ,

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnologycancer treatment stocksCancerTreatmentStockscelgcelgenedrug development stocksDrugDevelopmentStockshealthcare stocksHealthcareStocksian wyattIanWyattimmune disease stocksImmuneDiseaseStocksstem cell researchStemCellResearchsteven halpernStevenHalpernthestockadvisors.comtop stock insightsMon, 22 Jun 2009 13:40:00 EST